HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Heikki Sairanen Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petäjä, J. Articles by Siimes, M. A. Search for Related Content PubMed PubMed Citation Articles by Petäjä, J. Articles by Siimes, M. A.

J Thorac Cardiovasc Surg 1996;112:665-671
© 1996 Mosby, Inc.

SURGERY FOR CONGENITAL HEART DISEASE

FIBRINOLYSIS, ANTITHROMBIN III, AND PROTEIN C IN NEONATES DURING CARDIAC OPERATIONS

Received for publication Sept. 28, 1995 Revisions requested Dec. 6, 1995; revisions received Jan. 1, 1996 Accepted for publication Jan. 26, 1996. Address for reprints: Jari Petäjä, MD, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10666 North Torrey Pines Rd., SBR-5, La Jolla, CA 92037.

Abstract

Fibrinolysis and coagulation were studied in 10 neonates undergoing cardiac operations for congenital heart defects. Coagulation was activated during cardiopulmonary bypass as evidenced by highly increased prothrombin fragment 1+2 levels compared with preoperative values. Prothrombin fragment 1+2 levels remained elevated until postoperative day 3. Unlike coagulation, fibrinolysis was not activated during cardiopulmonary bypass but did show late activation on postoperative day 3, as evidenced by elevated levels of the fibrin degradation product D-dimer. Lack of fibrinolytic activation during bypass and its appearance on postoperative day 3 were partly explained by changes observed in tissue plasminogen activator and its inhibitor. During bypass, levels of tissue plasminogen activator and its inhibitor increased by 3.4-fold and 3.2-fold, respectively. In the postoperative period, levels of plasminogen activator inhibitor normalized rapidly whereas tissue plasminogen activator remained elevated, resulting in late fibrinolytic activation on postoperative day 3. In accordance with elevated prothrombin fragment 1+2, platelet count, antithrombin III, protein C, prothrombin, and factor VII were decreased on postoperative day 2, indicating ongoing consumptive coagulopathy. Nine patients had antithrombin III and six had protein C levels below age-specific normal ranges, consistent with an acquired deficiency state. Three had central venous thrombosis by postoperative day 4 or 5. In all three, thrombosis was preceded by antithrombin Ill deficiency, protein C deficiency, and highly elevated plasminogen activator inhibitor (3.7 to 37 times the mean of the other patients) on postoperative days 1 to 3. In conclusion, cardiopulmonary bypass in neonates caused rapid and profound alterations in the coagulation and fibrinolytic systems and initiated consumptive coagulopathy lasting until at least postoperative day 3. Thrombophilic abnormalities in antithrombin III, protein C, and fibrinolysis were frequently found and were associated with serious thrombotic complications. (J THORAC CARDIOVASC SURG 1996;112:665-71)

This article has been cited by other articles:

				L. K. Boshkov, A. Kirby, I. Shen, and R. M. Ungerleider Recognition and Management of Heparin-Induced Thrombocytopenia in Pediatric Cardiopulmonary Bypass Patients Ann. Thorac. Surg., June 1, 2006; 81(6): S2355 - S2359. [Abstract] [Full Text] [PDF]

				J. Jaggers and J. H. Lawson Coagulopathy and Inflammation in Neonatal Heart Surgery: Mechanisms and Strategies Ann. Thorac. Surg., June 1, 2006; 81(6): S2360 - S2366. [Full Text] [PDF]

				V. Bernet-Buettiker, K. Waldvogel, V. Cannizzaro, and M. Albisetti Antithrombin activity in children with chylothorax Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 406 - 409. [Abstract] [Full Text] [PDF]

				M. J. Eisses, K. Seidel, G. S. Aldea, and W. L. Chandler Reducing Hemostatic Activation During Cardiopulmonary Bypass: A Combined Approach Anesth. Analg., May 1, 2004; 98(5): 1208 - 1216. [Abstract] [Full Text] [PDF]

				E. Jensen, S. Andreasson, A. Bengtsson, H. Berggren, R. Ekroth, L. E. Larsson, and J. Ouchterlony Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system Ann. Thorac. Surg., March 1, 2004; 77(3): 962 - 967. [Abstract] [Full Text] [PDF]

				W. C. Oliver Jr Overview of Heparin and Protamine Management and Dosing Regimens in Pediatric Cardiac Surgical Patients Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 387 - 410. [Abstract] [PDF]

				H. Mossinger, W. Dietrich, S. L. Braun, M. Jochum, H. Meisner, and J. A. Richter High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): 430 - 437. [Abstract] [Full Text] [PDF]

				E. A. Bacha, J. Quinones, M. D. Kahana, J. M. Baron, and Z. M. Hijazi Embolic coronary occlusion after the arterial switch procedure J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 1028 - 1030. [Full Text] [PDF]

				J. Petaja, K. Peltola, and P. Rautiainen DISAPPEARANCE OF SYMPTOMATIC VENOUS THROMBOSIS AFTER NEONATAL CARDIAC OPERATIONS DURING ANTITHROMBIN III SUBSTITUTION J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 955 - 956. [Full Text] [PDF]